Table 1.
Demographics and Baseline Disease Characteristics in a Pooled Analysis of Patients With a PD‐L1 TPS < 1%
| Characteristic | Pembrolizumab + Chemotherapy (n = 256) | Chemotherapy Alone (n = 188) |
|---|---|---|
| Age | ||
| Median (range), y | 64.0 (34‐87) | 64.0 (37‐82) |
| <65 y, No. (%) | 131 (51.2) | 96 (51.1) |
| Male sex, No. (%) | 169 (66.0) | 133 (70.7) |
| Region of enrollment, No. (%) | ||
| Europe | 142 (55.5) | 89 (47.3) |
| North America | 60 (23.4) | 45 (23.9) |
| East Asia | 36 (14.1) | 29 (15.4) |
| Other | 18 (7.0) | 25 (13.3) |
| ECOG PS, No. (%) | ||
| 0 | 96 (37.5) | 72 (38.3) |
| 1 | 159 (62.1) | 116 (61.7) |
| 2 | 1 (0.4) | 0 |
| Smoking history, No. (%) | ||
| Current or former | 225 (87.9) | 174 (92.6) |
| Never | 31 (12.1) | 14 (7.4) |
| Histology, No. (%) | ||
| Squamous | 94 (36.7) | 99 (52.7) |
| Nonsquamous | 155 (60.5) | 83 (44.1) |
| Other | 7 (2.7) | 6 (3.2) |
| Brain metastases, No. (%) | 43 (16.8) | 26 (13.8) |
| Liver metastases, No. (%) | 38 (14.8) | 44 (23.4) |
| Previous therapy, No. (%) | ||
| Radiotherapy | 47 (18.4) | 41 (21.8) |
| Neoadjuvant | 4 (1.6) | 4 (2.1) |
| Adjuvant | 12 (4.7) | 8 (4.3) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD‐L1, programmed death ligand 1; PS, performance status; TPS, tumor proportion score.